Why the study?
Does platelet function testing reduce thromboembolic and hemorrhagic complications in patients undergoing flow diversion or percutaneous coronary interventions?
Does platelet function testing reduce thromboembolic and hemorrhagic complications in patients undergoing flow diversion or percutaneous coronary interventions?
Despite its prevalence, the clinical benefits of routine platelet function testing prior to flow diversion or percutaneous coronary interventions remain unproven.
Routine platelet function testing before PCI should not yet drive clinical decision-making; leaves open the need for.
OBJECTIVE Although the use of dual antiplatelet therapy with flow diversion is recommended and commonplace, the testing of platelet inhibition is more controversial. METHODS The authors reviewed the medical literature to establish and describe the physiology of platelet adhesion, the pharmacology of antiplatelet medications, and the mechanisms of the available platelet function tests. Additionally, they present a review of the pertinent neurointerventional and interventional cardiology literature. RESULTS Competing reports in the neurointerventional literature argue for and against the use of routine platelet function testing, with adjustments to the dosage or medications based on the results. The interventional cardiology literature has also wrestled with this dilemma after percutaneous coronary interventions, with conflicting reports of the benefits of platelet function testing. CONCLUSIONS Despite its prevalence, the benefits of platelet function testing prior to flow diversion are unproven. This practice will likely remain controversial until the level of evidence improves through more rigorous testing and reporting.
No takes yet. Share an insight, caveat, or question.
Taylor et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: